NASDAQ:MEIP - MEI Pharma Stock Price, Forecast & News

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

MEI Pharma Inc (NASDAQ:MEIP) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.11 million. MEI Pharma had a negative return on equity of 79.27% and a negative net margin of 514.11%. View MEI Pharma's Earnings History.

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for MEI Pharma.

3 equities research analysts have issued 1 year price objectives for MEI Pharma's shares. Their forecasts range from $10.00 to $10.00. On average, they expect MEI Pharma's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 329.2% from the stock's current price. View Analyst Price Targets for MEI Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

News headlines about MEIP stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MEI Pharma earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for MEI Pharma.

MEI Pharma saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 367,900 shares, an increase of 25.2% from the December 15th total of 293,800 shares. Based on an average daily trading volume, of 418,900 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.6% of the shares of the company are short sold. View MEI Pharma's Current Options Chain.

Some companies that are related to MEI Pharma include Amphastar Pharmaceuticals (AMPH), XBiotech (XBIT), G1 Therapeutics (GTHX), RAPT Therapeutics (RAPT), Phathom Pharmaceuticals (PHAT), Odonate Therapeutics (ODT), Gossamer Bio (GOSS), Applied Therapeutics (APLT), Achillion Pharmaceuticals (ACHN), Radius Health (RDUS), Aprea Therapeutics (APRE), Kiniksa Pharmaceuticals (KNSA), Provention Bio (PRVB), Endonovo Therapeutics (ENDV) and Rhythm Pharmaceuticals (RYTM).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include SCYNEXIS (SCYX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), Opko Health (OPK) and TG Therapeutics (TGTX).

MEI Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (8.38%), DAVENPORT & Co LLC (0.05%) and Strs Ohio (0.02%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, David M Urso and Thomas C Reynolds. View Institutional Ownership Trends for MEI Pharma.

MEIP stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, DAVENPORT & Co LLC and Strs Ohio. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold and Thomas C Reynolds. View Insider Buying and Selling for MEI Pharma.

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEIP stock can currently be purchased for approximately $2.33.

MEI Pharma has a market capitalization of $237.15 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

The official website for MEI Pharma is http://www.meipharma.com/.

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]